How Long Peptides Take to Work: Onset Timelines Reported in the Published Literature

Questions about how quickly peptide drugs "work" run into a basic feature of the clinical literature: trials rarely report a moment of onset. Instead, researchers pre-specify an endpoint, define a follow-up schedule, and report change from baseline at those visits. The answer to "how long" therefore depends almost entirely on which endpoint a given study measured and how long that study ran. This page summarises what the cited papers reported about their own timelines.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or health decision.

What "working" meant inside the published trials

In peptide trials of GLP-1 receptor agonists and related agents, the reported outcome is a group-level average at a scheduled assessment, not an individual turning point. The 2018 SUSTAIN 7 randomised, open-label phase 3b trial compared semaglutide with dulaglutide once weekly in patients with type 2 diabetes across 40 weeks of treatment, with glycemic outcomes reported at that endpoint (PMID 29397376). A reader looking for "the week it started working" would not find one in that design, because the study reported the comparison at its pre-specified timepoint.

A 2022 handbook review of drugs for treating obesity summarised the pharmacologic landscape in which these peptide agents sit, describing how agents are evaluated and compared rather than assigning a universal onset (PMID 34783910). That framing matters: across the literature, the measured interval is a protocol decision.

Reported study durations at a glance

Weeks to months: glycemic endpoints

The shortest reported windows in this set belong to glycemic comparisons. Researchers in SUSTAIN 7 randomised patients with type 2 diabetes to semaglutide or dulaglutide once weekly and reported outcomes over 40 weeks (PMID 29397376). Glycated haemoglobin, the standard glycemic measure in such trials, reflects an average over preceding weeks by design, which is one structural reason that glycemic endpoints in the peptide literature are reported across months rather than days.

Weekly administration schedules add a second structural feature. When a study administers a compound once weekly, as the SUSTAIN 7 investigators did (PMID 29397376), exposure accumulates across successive doses, and the reported endpoint reflects that accumulated period rather than any single administration.

Months to years: weight and risk-reduction endpoints

Trials measuring body weight, and especially those measuring disease-risk outcomes, ran considerably longer. A randomised, double-blind trial compared 3 years of liraglutide with placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes (PMID 28237263). Risk-reduction endpoints require enough time for events to accrue in both groups, which pushes such designs toward multi-year follow-up.

How long researchers followed participants for obesity endpoints

The 2025 New England Journal of Medicine report on tirzepatide for obesity treatment and diabetes prevention extended follow-up to 176 weeks, well beyond the horizon of a typical glycemic trial (PMID 39536238). Taken together with the 3-year liraglutide trial (PMID 28237263) and the 40-week SUSTAIN 7 comparison (PMID 29397376), the published durations for these peptide agents span roughly 40 weeks at the short end to 176 weeks at the long end, with the endpoint dictating the length.

Time course as its own research question

Some analyses treat timing explicitly rather than reporting only a final visit. A 2025 Sleep Medicine analysis of tirzepatide for sleep-disordered breathing in SURMOUNT-OSA examined the time course of change and its association with body weight, rather than presenting a single endpoint value (PMID 41135142). That kind of analysis is the closest the literature comes to answering "when did the change appear", because it plots measurements across scheduled visits and relates them to a concurrent variable.

Even there, the reported trajectory is an average across a randomised population. The study reported a population-level time course; it did not assign an onset date to any individual participant (PMID 41135142).

What was reported after treatment stopped

Timelines do not end when dosing ends, and some papers followed that interval. A 2-year observational study examined the maintenance of long-term weight loss after semaglutide withdrawal in obese women with polycystic ovary syndrome treated with metformin (PMID 38665260). Observational follow-up of this type describes what happened in a cohort after discontinuation; it is not a randomised comparison, and its findings are specific to the population and co-treatment described in the paper (PMID 38665260).

Why reported timelines differed between participants

Averages conceal spread. A 2025 Obesity analysis used clustering of intuitive eating and psychological health measures to identify subgroups associated with weight loss following semaglutide, indicating that researchers have looked for behavioural and psychological correlates of differing outcomes within the same treatment (PMID 40177856). The 2022 review of drugs for treating obesity likewise framed pharmacotherapy as one component evaluated within broader clinical management (PMID 34783910).

Practical consequences for interpretation:

• A trial's headline timepoint is the moment of measurement, not the moment of effect onset (PMID 29397376).
• Longer trials exist because their endpoints require longer accrual, as in the 3-year liraglutide trial (PMID 28237263) and the 176-week tirzepatide report (PMID 39536238).
• Subgroup analyses suggest heterogeneity within a single treated population (PMID 40177856).

Adverse Events and Their Timing: What Studies Report

Tolerability has its own reported timeline, and it is often shorter than the efficacy timeline. A 2022 real-world disproportionality study using the FDA Adverse Event Reporting System database examined the association between different GLP-1 receptor agonists and gastrointestinal adverse reactions (PMID 36568085). Disproportionality analyses of spontaneous reports describe reporting patterns across a database and cannot establish incidence or causation, a limitation the design carries by construction (PMID 36568085).

Case reports document individual events in detail. Researchers reported a case of liraglutide-associated acute pancreatitis (PMID 22345417), and a 2024 JCEM Case Reports paper described semaglutide-induced hyperemesis gravidarum (PMID 38249445). Single cases describe what happened to one patient and do not establish frequency across a population.

Preclinical timelines are not human timelines

Animal work operates on a different clock and a different question. A 2024 study in Acta Pharmacologica Sinica reported that empagliflozin and liraglutide ameliorated heart failure with preserved ejection fraction in mice via augmenting the Erbb4 signalling pathway (PMID 38589689). Mechanistic rodent studies of this kind investigate pathways in a model organism; the interval over which a mouse model changes does not translate into an expected human interval, and the cited paper did not make such a translation (PMID 38589689).

Why anecdotal photo comparisons do not match trial reporting

Paired personal photographs circulate widely, but they are not a data format the literature uses. Trials report mean change from baseline, dispersion, dropouts and pre-specified statistical comparisons at fixed visits, as in the 40-week SUSTAIN 7 comparison (PMID 29397376) and the 176-week tirzepatide report (PMID 39536238). An unblinded, unverified personal comparison has no control group, no fixed measurement schedule and no way to separate the compound from diet, activity, illness or measurement error. Clustering analyses that found subgroups with differing weight-loss outcomes following semaglutide illustrate how much individual variation can exist inside one trial population (PMID 40177856).

Limitations when comparing timelines across papers

Comparisons between studies are constrained by differences in population, comparator, endpoint and duration. A trial in prediabetes (PMID 28237263) is not interchangeable with a trial in type 2 diabetes (PMID 29397376) or with an observational cohort of women with PCOS after drug withdrawal (PMID 38665260). Annual review articles exist partly to manage this problem; the 2025 Osteoarthritis and Cartilage year in review synthesised the year's epidemiology and therapy literature in a single field, showing how reviewers aggregate studies of differing designs and follow-up lengths rather than averaging their timelines directly (PMID 40914550).

Many compounds discussed in peptide communities have no comparable trial literature at all. Where research-use-only materials are concerned, published human timelines may not exist, and the absence of a reported onset window is not evidence of a fast one. Regulatory approval status, where it exists, attaches to specific products, indications and manufacturing standards.

Again, this page is for educational purposes only and is not medical advice; consult a licensed physician regarding any medication, symptom or treatment timeline.

References

• Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial (The Lancet Diabetes & Endocrinology, 2018)
• 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial (Lancet, 2017)
• Tirzepatide for Obesity Treatment and Diabetes Prevention (The New England Journal of Medicine, 2025)
• Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight (Sleep Medicine, 2025)
• The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study (Frontiers in Endocrinology, 2024)
• Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide (Obesity, 2025)
• Drugs for Treating Obesity (Handbook of Experimental Pharmacology, 2022)
• Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database (Frontiers in Endocrinology, 2022)
• Liraglutide-associated acute pancreatitis (American Journal of Health-System Pharmacy, 2012)
• Semaglutide-induced Hyperemesis Gravidarum (JCEM Case Reports, 2024)
• Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway (Acta Pharmacologica Sinica, 2024)
• Osteoarthritis year in review 2025: Epidemiology and therapy (Osteoarthritis and Cartilage, 2025)